Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Neuroimaging in schizophrenia].

R Lanzenberger1, S Kasper

  • 1Klinische Abteilung für Allgemeine Psychiatrie, Medizinische Universität Wien/Osterreich.

Fortschritte Der Neurologie-Psychiatrie
|November 5, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fruquintinib in combination with tislelizumab versus trifluridine/tipiracil and bevacizumab in third-line and beyond MSS mCRC without active liver metastases-the IKF-080/AIO-QUINTIS trial.

ESMO gastrointestinal oncology·2026
Same author

Virtual reality support during systemic cancer therapy to improve anxiety/depressive symptoms and reduce toxicity in patients with gastrointestinal cancers-OncoVR.

ESMO gastrointestinal oncology·2026
Same author

TROPHIT1-a randomized, open-label, multicenter, phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patients.

ESMO gastrointestinal oncology·2026
Same author

Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases-the PURPLE trial.

ESMO gastrointestinal oncology·2026
Same author

Human <i>in vivo</i> assessment of ketamine binding of the serotonin transporter-follow up at a higher dose.

Frontiers in neuroscience·2025
Same author

Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2.

ESMO open·2025
Same journal

[Rare hereditary and acquired diseases with parkinson's syndrome].

Fortschritte der Neurologie-Psychiatrie·2026
Same journal

[Digital transformation in multiple sclerosis: Advances in diagnostics, monitoring and patient-centred care].

Fortschritte der Neurologie-Psychiatrie·2026
Same journal

[Dementia with Lewy bodies].

Fortschritte der Neurologie-Psychiatrie·2026
Same journal

[Impact of the PEPP reimbursement system and other developments on inpatient care of general psychiatry patients 2005 to 2022: a retrospective analysis].

Fortschritte der Neurologie-Psychiatrie·2026
Same journal

[The pathology of the brain eating amoeba Naegleria fowleri].

Fortschritte der Neurologie-Psychiatrie·2026
Same journal

[Chronic vestibular syndromes: Correct diagnosis and treatment].

Fortschritte der Neurologie-Psychiatrie·2026
See all related articles

Functional neuroimaging reveals dopamine dysregulation in schizophrenia. Studies using PET and fMRI show altered neurotransmitter activity and brain connectivity, suggesting potential biological markers for the disorder.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Radiology

Background:

  • Schizophrenia is increasingly understood through the lens of the dopamine hypothesis.
  • Functional neuroimaging techniques offer insights into brain function and neurotransmitter systems.

Purpose of the Study:

  • To review functional neuroimaging evidence supporting the dopamine hypothesis of schizophrenia.
  • To explore alterations in dopaminergic neurotransmission, receptor binding, and brain connectivity in schizophrenia.
  • To discuss the potential of neuroimaging for developing diagnostic biomarkers.

Main Methods:

  • Review of functional neuroimaging studies, including functional magnetic resonance imaging (fMRI), positron emission tomography (PET), and single photon emission computed tomography (SPECT).
  • Analysis of dopaminergic challenge studies using amphetamine and alpha-methyl-para-tyrosine (AMPT).

Related Experiment Videos

  • Examination of neuroimaging data related to glutamatergic dysfunction, serotonin receptor binding, and genetic influences (COMT).

    • Main Results:

    • PET and SPECT studies indicate increased amphetamine-induced dopamine release and decreased AMPT-induced dopamine depletion in drug-naive schizophrenia patients.
    • fMRI and PET reveal altered task-specific functional connectivity, particularly in the prefrontal cortex and temporal structures.
    • Increased serotonin-1A receptor binding potential and COMT gene effects on prefrontal activation are observed.

    Conclusions:

    • Functional neuroimaging, especially challenge paradigms and task-based fMRI, provides strong evidence for dopaminergic dysregulation in schizophrenia.
    • These neuroimaging approaches show promise for the development of objective biological marker tests for schizophrenia.